Intellia Therapeutics, Inc. (NTLA) Institutional Ownership

Ownership Summary

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has 286 institutional investors with active 13F positions as of December 2025.

• They owned 94.6% of outstanding stock in December 2025, down from 96.3% the prior quarter.
• Their total shares held in NTLA increased 4.97% from the prior quarter, while the number of investors in Intellia Therapeutics decreased 0.69% year over year.
• Of these 286 holders, 159 added to their stakes in Intellia Therapeutics, 87 trimmed positions, and 40 made no changes.
• In total, institutional investors held 104.18Mn shares in Intellia Therapeutics as of December 2025, up by 4.94Mn shares quarter on quarter, and down 446.24K shares year over year.
• As of December 31, 2025, the biggest holder of Intellia Therapeutics is ARK Investment Management LLC at 14.51Mn shares, representing 13.17% of shares outstanding.
• Leading buyers of Intellia Therapeutics shares for the quarter ending December 2025 were VANGUARD PORTFOLIO MANAGEMENT LLC (6.22Mn), VANGUARD CAPITAL MANAGEMENT LLC (5.08Mn), TWO SIGMA INVESTMENTS, LP (2.01Mn), BlackRock, Inc. (1.88Mn), UBS Group AG (1.83Mn).
• The biggest sellers of Intellia Therapeutics for the quarter ending December 2025 included Goldman Sachs Group Inc (1.28Mn), ARMISTICE CAPITAL, LLC (820.0K), CITADEL ADVISORS LLC (492.01K), Barclays Plc (364.0K), HRT FINANCIAL LP (262.55K).
• Business Quant data shows the 10 biggest positions in Intellia Therapeutics as of December 2025 are held by ARK Investment Management LLC (14.51Mn), BlackRock, Inc. (12.16Mn), State Street Corp (6.92Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (6.22Mn), D. E. Shaw & Co., Inc. (5.73Mn), VANGUARD CAPITAL MANAGEMENT LLC (5.08Mn), TWO SIGMA INVESTMENTS, LP (4.71Mn), Regeneron Pharmaceuticals, Inc. (3.7Mn), GEODE CAPITAL MANAGEMENT, LLC (2.85Mn), UBS Group AG (2.69Mn).